Sensirion to start production of SHT21 sensor

Published: 29-Mar-2010
Regulatory

Swiss manufacturer says it is the smallest digital humidity sensor in the world

Sensirion, a Swiss manufacturer of CMOS-based sensor components and systems, is to begin serial production of the SHT21 next month (April).

The SHT21 consists of a newly designed sensor chip encapsulated in a DFN 3-0 package. With this encapsulation the chip is completely over-moulded, except for the humidity sensing area. This reduces the component’s size to 3x3mm with a height of 1.1mm. The company says it also provides protection against condensation and harsh environments, therefore giving outstanding long-term stability.

Typical sensor accuracy is ±2% RH over 20–80% RH and ±0.3 °C over 25–42°C.

A scan path routine enables detailed sensor quality checking, while individual detailed tracking information on the chip can be read out by a simple command. Additionally, the SHT21 is reflow solderable without any degradation of sensor performance. The sensor is provided on tape and reel to facilitate trouble-free handling.

See more

You may also like

Regulatory

3PBIOVIAN secures French CIR certification for Spain and Finland R&D sites

Read more
The CDMO has obtained French Crédit d’Impôt Recherche (CIR) certification for its Pamplona and Turku sites, enabling French partners to access tax incentives when collaborating on recombinant protein and advanced therapy projects

Trending Articles

  1. Shilpa Medicare targets US approval for extended-release Ondansetron injection for CINV Shilpa Medicare plans to pursue US approval and licensing partners for OERIS after a Phase III study in India met all primary and secondary endpoints and showed a strong safety profile in chemotherapy-induced nausea and vomiting
  2. 3PBIOVIAN secures French CIR certification for Spain and Finland R&D sites The CDMO has obtained French Crédit d’Impôt Recherche (CIR) certification for its Pamplona and Turku sites, enabling French partners to access tax incentives when collaborating on recombinant protein and advanced therapy projects
  3. MedPharm completes FDA inspection of manufacturing plant in Durham The topical drug product manufacturing facility in North Carolina successfully completed its FDA inspection for the commercial manufacture of drug products with no Form 483 issued plus an NAI classification
  4. New thermal inkjet printer expands AM Labels’ coding portfolio M2 system delivers high resolution variable data printing at production-line speeds
  5. Ascletis secures FDA IND clearance for Phase II Study of oral GLP-1 candidate in type 2 diabetes Ascletis has received US FDA IND clearance to begin a 13-week Phase II trial of ASC30, its oral small-molecule GLP-1 receptor agonist, evaluating efficacy, safety and tolerability in people with type 2 diabetes

Upcoming event

Pharmapack

21–22 January 2026 | Exhibition | Paris, France See all

You may also like

Regulatory

3PBIOVIAN secures French CIR certification for Spain and Finland R&D sites

The CDMO has obtained French Crédit d’Impôt Recherche (CIR) certification for its Pamplona and Turku sites, enabling French partners to access tax incentives when collaborating on recombinant protein and advanced therapy projects
Regulatory

Shilpa Medicare targets US approval for extended-release Ondansetron injection for CINV

Shilpa Medicare plans to pursue US approval and licensing partners for OERIS after a Phase III study in India met all primary and secondary endpoints and showed a strong safety profile in chemotherapy-induced nausea and vomiting
Manufacturing

MedPharm completes FDA inspection of manufacturing plant in Durham

The topical drug product manufacturing facility in North Carolina successfully completed its FDA inspection for the commercial manufacture of drug products with no Form 483 issued plus an NAI classification
Manufacturing

New thermal inkjet printer expands AM Labels’ coding portfolio

M2 system delivers high resolution variable data printing at production-line speeds
Regulatory

Ascletis secures FDA IND clearance for Phase II Study of oral GLP-1 candidate in type 2 diabetes

Ascletis has received US FDA IND clearance to begin a 13-week Phase II trial of ASC30, its oral small-molecule GLP-1 receptor agonist, evaluating efficacy, safety and tolerability in people with type 2 diabetes
Regulatory

Novo Nordisk wins positive ruling for semaglutide compound patent from China’s Supreme People’s Court

The company has welcomed a decision by China’s Supreme People’s Court affirming the validity of its semaglutide compound patent, strengthening confidence for foreign drugmakers operating in the Chinese market
Regulatory

Grifols receives US FDA approval for new fibrinogen concentrate: FESILTY (fibrinogen, human-chmt)

The fibrinogen concentrate complements Grifols’ bleeding management portfolio, expanding therapeutic options for patients
Subscribe now